

## **REMARKS/ARGUMENTS**

### ***Response to the Restriction***

In response to the restriction requirement, Applicants elect Group I, claims 1-5 and 12-16, drawn to methods of treating migraine comprising administering to a subject in need thereof an amount of a glucocorticoid receptor antagonist. Applicants further elect the species of specific steroidal glucocorticoid receptor antagonists devoid of progesterone receptor binding activity.

The foregoing election is made with traverse, as the groups and species set forth by the Examiner stem from a common concept and theory, and are thus related. In particular, glucocorticoid receptor antagonists are all effective for treating migraine because they prevent agonist binding to the glucocorticoid receptor. These compounds share a common function, irrespective of their particular structural features. As such, prosecution of the claims of Groups I-II and the genus of glucocorticoid receptor antagonists would not place a substantially greater burden on the Examiner. Applicants therefore respectfully request that the Examiner withdraw the restriction requirement and consider all the claims together.

### ***Status of the claims***

Applicants further submit herewith amendments to the claims. With this amendment, claims 1-5 and 12-16 are pending. Claims 6-11 and 17-21 are canceled. However, Applicants reserve the right to pursue the subject matter of the canceled claims in later prosecution.


Claim 1 is amended. Support for the amendment is found throughout the specification as filed. In particular, specific glucocorticoid receptor antagonists are described, *e.g.*, in paragraph [29] of the published application US 2006/0052354. Steroidal glucocorticoid receptor antagonists devoid of progesterone binding activity are described, *e.g.*, in paragraph [53].

**CONCLUSION**

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Carol P. Johns  
Reg. No. 50,463

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
Attachments  
CPJ:cpj  
61200222 v1